Novo Nordisk Launches Low-Priced Insulin In US
Introduces Authorized Generics Of Its NovoLog And NovoLog Mix
Novo Nordisk says it is offering solutions to the unaffordability and inaccessibility of insulin by launching US authorized generics of its NovoLog and NovoLog Mix brands. The originator is also introducing a ‘My$99Insulin’ plan and an ‘immediate supply’ option to “help people with diabetes who need alternative solutions.”
You may also be interested in...
With rebate reform efforts stalled, insulin manufacturer broadens efforts to lower prices through authorized generics, but PBMs may still like the big rebates they can get on the original brands.
Novo Nordisk will launch US authorized generics of its NovoLog and NovoLog Mix at half the price of the brands from the start of 2020.
Armas has kicked off 2020 with the launch of four generic injectables in the US.